Fat, Inflammation and Insulin Resistance (FIRE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The combination of impaired insulin sensitivity and insulin secretion is thought to be the basis of type 2 diabetes. Increased free fatty acids levels impair insulin action in muscle and liver, but also systemic inflammation processes play a role in the development of insulin resistance.
This study compares the effects of fat and inflammation on insulin sensitivity, systemic inflammation, energy metabolism, vascular system and neural function in healthy humans.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy Adults With Normal BMI |
Biological: Fat/Inflammation effects |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Fat, Inflammation and Insulin Resistance (FIRE-Study) |
- Effect of intervention on whole body insulin sensitivity [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
- Effect of intervention on systemic inflammation [ Time Frame: 1-6 hours ] [ Designated as safety issue: No ]
- Effect of intervention on cellular immune mechanisms [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
| Enrollment: | 16 |
| Study Start Date: | March 2009 |
| Estimated Study Completion Date: | October 2012 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Fat intravenously
Intravenous application of fat
|
Biological: Fat/Inflammation effects
Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
|
|
Active Comparator: Fat orally
Oral fat load
|
Biological: Fat/Inflammation effects
Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
|
|
Active Comparator: LPS intravenously
Lipopolysaccharide (LPS; US Standard Reference endotoxin)
|
Biological: Fat/Inflammation effects
Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
|
|
Placebo Comparator: Glycerol intravenously
Intrevenous glycerol infusion
|
Biological: Fat/Inflammation effects
Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
|
Detailed Description:
A dysregulation of lipid metabolism with increased levels of free fatty acids (FFA) is known represent one key mechanism in the pathophysiology of insulin resistance, which is subsequently known to be the basis of the development of type 2 diabetes. But also inflammatory processes, also known as subclinical inflammation, have been shown to be independently associated with insulin resistance and diabetes development. The aim of this study is to analyse the causal relationship between FFA and inflammation in the induction of insulin resistance in healthy humans.
It is known that the parenteral application of lipids over 4-6 hours results in an increase of FFA and a subsequent induction of a transient insulin resistance in peripheral tissues. Whether oral fat intake has similar effect is still unknown. On the other hand the oral intake of a high fat meal acutely increases intestinal permeability and thereby the levels of bacterial lipopolysaccharide (LPS) in the bloodstream. LPS is known to be a potent stimulator of immune response on a subclinical level accompanied by elevated levels of immune mediators, which in turn impair the insulin receptor signalling pathway leading to insulin resistance. Thus, in this study the effects of fat, both by an oral or parenteral fat load, and by a short-term LPS-infusion simulating the postprandial systemic LPS peak compared to a control infusion (glycerol) on insulin resistance is analysed. Insulin resistance and hepatic glucose production is determined by an hyperinsulinemic euglycemic clamp including glucose tracers. To detect the effects on the immune system on different levels, we measure 1) circulating levels of immune mediators by ELISA and bead-based mulitiplex assays, 2) gene expression of leukocytes, 3) subfractions of circulating leukocytes by FACS and 4) the stimulatory capacity of isolated lymphocytes and monocytes in vitro. Moreover, the effects of fat or inflammation on the function of the autonomic nervous system and the vasculature are studied. A second focus is the impact of the interventions on signal transduction and mitochondrial function in muscle and as well as on the metabolism and inflammation in subcutaneous adipose tissue in muscle and fat biopsies.
Eligibility| Ages Eligible for Study: | 20 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy male and female subjects
- Age 20-40
- BMI 20-25 mg/m2
Exclusion Criteria:
- Hyperlipidemia
- Smoking
- Pregnancy
- Acute infection
- Anaemia
- Taking drugs influencing lipid or glucose metabolism, the immune system or antihypertensive medication
- Malignancies
- Any chronic disease
- Autoimmune or immune compromising diseases including HIV/AIDS
- Allergies against study drugs
- Hepatitis
- Gall bladder diseases
- Renal failure
- Psychiatric diseases or addiction
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Bettina Nowotny, Dr. Bettina Nowotny, M.Sc., German Diabetes Center |
| ClinicalTrials.gov Identifier: | NCT01054989 History of Changes |
| Other Study ID Numbers: | FIRE-01 |
| Study First Received: | January 22, 2010 |
| Last Updated: | July 12, 2012 |
| Health Authority: | Germany: Ethics Commission Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by German Diabetes Center:
|
Healthy adults Insulin sensitivity |
Additional relevant MeSH terms:
|
Inflammation Insulin Resistance Pathologic Processes Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Glycerol |
Insulin Cryoprotective Agents Protective Agents Physiological Effects of Drugs Pharmacologic Actions Hypoglycemic Agents |
ClinicalTrials.gov processed this record on May 19, 2013